Here's Why Omeros Stock Is Tanking Today
Shares of Omeros (NASDAQ: OMER), a biopharmaceutical company, are falling today after the company made a disclosure regarding narsoplimab, an experimental treatment to address side effects of stem cell transplants. Omeros has just one revenue stream at the moment, Omidria, an expensive eye-drop solution that gets added to the bill when Medicare patients go under the knife for lens replacements and cataract removals.